Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi & miRNA

Karen Bulock's Biography



Karen Bulock, Associate Director/Vice President, RXi Pharmaceuticals

Dr. Bulock has twenty years of experience in discovery project management and assay development. During her tenure at RXi Pharmaceuticals, Dr. Bulock has managed several key programs leading to the discovery and preclinical development of RXI-109 for dermal scarring and fibrosis.  Prior to this she spent several years leading small molecule drug discovery programs at CytRx, Corporation.  Dr. Bulock received a Ph.D. in Pharmacology from Yale University.

Karen Bulock Image

Asymmetric, Hydrophobically Modified RNAi Compounds: From Mechanism of Action to Clinical Development

Thursday, 19 April 2012 at 16:00

Add to Calendar ▼2012-04-19 16:00:002012-04-19 17:00:00Europe/LondonAsymmetric, Hydrophobically Modified RNAi Compounds: From Mechanism of Action to Clinical DevelopmentSELECTBIOenquiries@selectbiosciences.com

This presentation will provide an overview of our recent work to develop sd-rxRNA®, a class of improved RNAi compounds that are readily taken up by cells without any delivery vehicle or formulation.  Data supporting the potential therapeutic uses of sd-rxRNA will be presented.


Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonRNAi and miRNASELECTBIOenquiries@selectbiosciences.com